Nuclear medicine in cancer diagnosis

Lancet

Volumn 354, Issue 9181, 1999, Pages 853-857

  Eary, Janet F ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE SCINTISCANNING; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; HUMAN; NUCLEAR MEDICINE; PATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; TREATMENT PLANNING;

EID: 0033523389     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)80041-5     Document Type: Review

References (45)

1. Hendler A, Hershkop M. When to use bone scintigraphy: it can reveal things other studies cannot. Postgrad Med. 104:1998;54-56.
2. Hendler A, Hershkop M. When to use bone scintigraphy: it can reveal things other studies cannot. Postgrad Med. 104:1998;59-61.
3. Hendler A, Hershkop M. When to use bone scintigraphy: it can reveal things other studies cannot. Postgrad Med. 104:1998;65-66.
4. Warburg OH. The metabolism of tumors. 1931;Richard B Smith, New York.
5. Som P. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med. 21:1980;670-675.
6. Wahl RL, DeVita VT, Hellman S, Rosenberg SA. PPO update: vol 1/2. 1998;Lippincott-Raven, Philadelphia.
7. Gupta NC, et al. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 184:1992;441-444.
8. Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol. 16:1998;1075-1084.
9. Weder W, Schmid RA, Bruchhaus H, Hillinger S, von Schultess GK, Steinert HC. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thoracic Surg. 66:1998;886-893.
10. Yonekura Y, Benua RS, Brill AB, et al. Increased accumulation of 2-deoxy-2-[18F]fluoro-D-glucose in liver metastases from colon carcinoma. J Nucl Med. 23:1982;1133-1137.
11. Schiepers C, Penninck F, De Vadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol. 21:1995;517-522.
12. Delbeke D, Vitola JV, Sandler MP, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 38:1997;1196-1201.
13. Newman JS, Francis IR, Kaminski MS, et al. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology. 190:1994;111-116.
14. Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease in lymphoma. J Nucl Med. 38:1997;343-348.
15. Bares R, Klever P, Hauptmann S, et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology. 192:1994;79-86.
16. Karlan BY, Hawkins R, Hoh C, et al. Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol. 51:1993;175-181.
17. Feine U, Lietzenmayer R, Henke JP, et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 37:1996;1468-1472.
18. Eary JF, Conrad EU, Bruckner JB, Folpe A, Hunt KJ, Mankoff DM, Howlett AT. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pre-treatment and grading of sarcoma. Clin Cancer Res. 4:1998;1215-1220.
19. Zuckier LS, DeNardo GL. Trials and tribulations: oncological antibody imaging comes to the fore. Semin Nucl Med. 27:1997;10-29.
20. Lamberts SW, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med. 323:1990;1246-1249.
21. Pollen JJ, Witzum KF, Ashburn WL. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR. 142:1984;772-776.
22. Choi BW, Berger HJ, Schwartz PG, Wackers FJ, Gottschalk A, Zaret BL. Serial radionuclide assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiography. N Engl J Med. 300:1979;278-283.
23. Druck MN, Gulenchyn KY, Evans WK, et al. Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity. Cancer. 53:1984;1167-1174.
24. Price P, Jones T. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? Eur J Cancer. 31:1995;1924-1927.
25. Hoekstra OS, Ossenkoppele GJ, Golding R. Early treatment response in malignant lymphoma, as determined by planar fluorine-18 fluorodeoxyglucose scintigraphy. J Nucl Med. 34:1993;1706-1710.
26. Reisser C, Haberkorn U, Strauss LG. The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumours. J Otolaryngol. 22:1993;231-238.
27. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Biol. 34:1993;12-17.
28. Reinhardt MJ, Kubota K, Yamada S, Iwata R, Yaegashi H. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. J Nucl Med. 38:1997;280-287.
29. Minn H, Paul R, Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med. 29:1988;1521-1525.
30. Chaiken L, Rege S, Hoh C, et al. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Int J Radiat Oncol Biol Phys. 27:1993;455-464.
31. Ichiya Y, Kuwabara Y, Sasaki M, et al. A clinical evaluation of FDG-PET to assess the response to radiation therapy of bronchogenic carcinoma. Ann Nucl Med. 10:1996;193-200.
32. Doyle WK, Budinger TF, Valk PE, et al. Differentiation of cerebral radiation necrosis from tumor recurrence by [18F]FDG and 82Rb positron emission tomography. J Comput Assist Tomogr. 11:1987;563-570.
33. de Wit M, Bumann D, Beyer W, et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol. 8:1997;57-60. (suppl).
34. Shields AF, Mankoff DA, Link JM, et al. [C-11]thymidine and FDG to measure therapy response. J Nucl Med. 39:1998;1757-1762.
35. Eary JF, Mankoff DA, O'Sullivan F, Spence AM, Berger M, Olshen A, Link JM, Krohn KA. 2-[C-11]thymidine imaging in malignant brain tumors. Cancer Res. 59:1999;615-621.
36. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzok O, Mangner TJ. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 4:1998;1334-1336.
37. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human non-small cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Rad Oncol Biol Phys. 33:1995;391-398.
38. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys. 22:1992;199-212.
39. Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [F-18]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 36:1996;417-428.
40. Wilson DC, Eary JF, Conrad EU, Quantitative FMISO PET analysis of hypoxia in soft tissue sarcomas: correlation with F-18 FDG uptake, VEGF expression and tumor aggressiveness. Clin Cancer Res (in press).
41. Mintun MA, Welch MJ, Siegel BA, et al. JA. Breast cancer: PET imaging of estrogen receptors. Radiology. 169:1988;45-48.
42. Mankoff DA, Tewson TJ, Eary JF. Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer, [F-18]-16α-fluoroestradiol (FES). Nucl Med Biol. 24:1997;341-348.
43. Hu S, Shievely L, Raubitschek A, et al. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 56:1996;3055-3061.
44. Blankenberg FG, Katsikis PD, Tait JF, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Nat Acad Sci USA. 95:1998;6349-6354.
45. Tavitian B, Terrazzino S, Kuhnast B, et al. In vivo imaging of oligonucleotides with positron emission tomography. Nat Med. 4:1998;467-471.